According to the newest market research study by Technavio, the global anticoagulant market is predicted to grow at a CAGR of over 7% during the forecast period 2017 to 2021.
This industry report by Technavio provides an exhaustive analysis of the global anticoagulant market in terms of revenue and developing market trends. The report also contains the latest analysis and forecasts for various market sectors and all geographical regions.
Technavio research analysts sort the market based on the drug class
Click here to request a free sample of this report
The top three revenue-generating drug class segments are discussed below:
Global factor Xa inhibitors market: Factor Xa inhibitors are commonly known as prothrombinase or Stuart-Power factor, and it inhibits the action of factor Xa at the end of both intrinsic and extrinsic pathways. These inhibitors prevent the formation of thrombin, thus inhibiting the formation of clots. Furthermore, these medicines can be administered orally and show rapid onset of action with more efficacious pharmacodynamics and pharmacokinetic property. Such varied properties of these drugs will help in the growth of this market segment.
“Various drug approvals acquired for these agents will increase the adoption of these products in the global anticoagulant market over the next few years. Some of the drug approval acquired include rivaroxaban (XARELTO), edoxaban (SAVAYSA), and apixiban (ELIQUIS). Moreover, the recent approval of the factor Xa inhibitor reversal agent, andexanet alfa, developed by Portola Pharmaceuticals is expected to grow at a high rate in the global market,” says Sapna Jha, a lead analyst at Technavio for research on infectious and rare diseases.
Global heparin market: The entry of more generics will boost the growth of heparin market during the forecast period. These are a type of blood thinner that prevents blood clots and are produced by basophils and mast cells and is stored within the mast cells and secreted at the injury site to clot the blood. These drugs are taken from outside and are derived from natural sources such as pig intestine and bovine lungs, which enable the body’s natural clot lysis mechanisms to dissolve clots.
Global direct thrombin inhibitor market: DTIs are drugs that directly inhibit the enzyme thrombin, which is the activated factor IIa, resulting in blood clotting. Direct thrombin inhibitors are available as both soluble and fibrin-bound and are more predictable anticoagulant effect compared with heparins due to lack of binding to other plasma proteins. The PRADAXA is the only DTI available in the anticoagulant market.
Ask an analyst to know more about this report
The leading players operating in the global anticoagulant market are:
- Bayer HealthCare
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi Sankyo
- Johnson & Johnson
- Sanofi
The other key vendors in the market include AstraZeneca, Eli Lilly, Keryx Biopharmaceuticals, LEO Pharma, Pfizer, and The Medicines Company.
A more thorough analysis is offered in the Technavio report titled, ‘Global Anticoagulant Market 2017-2021’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Venous Thromboembolism Therapeutics Market 2017-2021
- Global Epinephrine Autoinjector Market 2017-2021
- Global Blood Coagulation Analyzer Market 2016-2020
To read more press releases – click here
